Seres Therapeutics (MCRB) Tops Q3 EPS by 94c

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of $0.94. Revenue for the quarter came in at $350 thousand.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Edge Total Intelligence Provides Business Update: Preliminary Second Quarter and First-Half Revenue, Special AGM Matters, and Strategic Growth
• Celcuity (CELC) Reiterates at Market Outperform by Citizens Ahead of Upcoming Launch